Labeesity®

SFK7® is a standardized extract derived from Labisia pumila, a traditional herb native to Southeast Asia. It has gained recognition as a potential dietary ingredient due to its various health benefits. Notably, SFK7® has obtained approval as a New Dietary Ingredient from the US Food and Drug Administration (FDA) and has also received recognition as a Novel Food from the European Food Safety Authority (EFSA).

Extensive pre-clinical studies have been conducted on SFK7® to explore its potential in addressing obesity, diabetes, and cancer. These studies involved laboratory testing and animal models, examining the effects of SFK7® on these health conditions. The results of these pre-clinical studies have shown promising outcomes, indicating the potential therapeutic properties of SFK7® in managing obesity, diabetes, and cancer.

Cardiovascular Health; Immune Health; Extensive pre-clinical studies have been conducted on SFK7® to explore its potential in addressing obesity, diabetes, and cancer. These studies involved laboratory testing and animal models, examining the effects of SFK7® on these health conditions. The results of these pre-clinical studies have shown promising outcomes, indicating the potential therapeutic properties of SFK7® in managing obesity, diabetes, and cancer.

Furthermore, SFK7® has progressed to Phase 2 randomized controlled trials (RCTs) that specifically target obesity in Malaysia and Indonesia. The successful completion of Phase 2 RCTs in these countries suggests positive outcomes and supports the potential use of SFK7® for managing obesity.

Currently, SFK7® is in the process of conducting Phase 3 studies in Malaysia, which is being carried out in conjunction with the submission of an IND (Investigational New Drug) application to the US FDA.

Standardized Extract Labisia pumila (SFK7®)

Malaysia

milligram